India's Orchid Establishes Japanese Subsidiary
This article was originally published in PharmAsia News
Indian pharmaceutical company Orchid Chemicals and Pharmaceuticals set up a Japanese subsidiary, Orchid Pharma Japan, the company announced April 10. Orchid Managing Director C.B. Rao commented the Tokyo-based branch will tap the rapidly growing Japanese generics market, and plans to launch five to ten drugs and reach ¥10 billion in sales in five years. Orchid Pharma Japan President Kunihiko Iwate said the short term goal for the company is to strengthen sales in the Japanese generics market. (Click here for more - Japanese language
You may also be interested in...
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.
Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.